Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.23.3
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 27 Months Ended
Jul. 01, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2024
Disaggregation of Revenue [Line Items]            
Total revenue   $ 236 $ 14,949 $ 1,353 $ 17,155  
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio            
Disaggregation of Revenue [Line Items]            
Other long-term debt   900   900    
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Forecast            
Disaggregation of Revenue [Line Items]            
Proceeds from divestiture of businesses           $ 1,000
Product revenue, net            
Disaggregation of Revenue [Line Items]            
Total revenue   $ 236 $ 432 $ 1,353 $ 2,638  
Millipred | Teva            
Disaggregation of Revenue [Line Items]            
Percent of net profit for installment payments 50.00%          
Installment payment $ 500          
Major Customer Number One | Sales Revenue | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage   72.00%   58.00%    
Major Customer Number Two | Sales Revenue | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage   28.00%   42.00%